Lupus News

In 2023, Healio had questions, the experts had answers.

In rheumatology, the next generation of new therapies always seems to be just out of reach, or perpetually “only a few years” away. However, several novel, and not-so-novel, approaches are giving hope that the future may finally soon arrive.

SAN DIEGO — Patients with systemic lupus erythematosus who are positive for antiphospholipid antibodies have a greater risk for future atherosclerotic cardiovascular disease, according to data presented at ACR Convergence 2023.

People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.

Come the new year, a “mini” pill could have a massive impact in rheumatology care.

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.

In this episode of Meeting Mic, we bring you Healio’s top headlines from ACR Convergence 2023.

Oral brepocitinib failed to meet its primary endpoint in a phase 2 trial of adults with moderate to severe lupus, according to a press release from the manufacturer.

The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone equivalent or less, according to the updated 2023 EULAR recommendations for the management of systemic lupus erythematosus.

As of just a few years ago, early enthusiasm over the apparent interplay between the gut microbiome and the immune system, and that it was driving or exacerbating certain rheumatic diseases, seemed to have all but dried up.